Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$13.8MCash on Hand
9.7mo Cash Runway
Follow CALC by emailGet an email when CALC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CALC, unsubscribe in one click. Privacy
📣 What CALC Says Is Next
mid-2027 · “CalciMedica is advancing CM5480 for pulmonary hypertension, including PAH and combined pre- and post-capillary pulmonary hypertension associated with heart failure with preserved ejection fraction, and anticipates submitting an IND in mid-2027.”
Company press release, Nov 10, 2026 · SEC filing
mid-2027 · “Pulmonary hypertension: CalciMedica plans to conduct a Phase 1b proof-of-concept trial, with data anticipated in mid-2027.”
Company press release, Nov 10, 2026 · SEC filing
by year-end · Auxora: “Details on this trial and the target patient population are expected by year-end with data anticipated in mid-2027.”
Company press release, Nov 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 10, 2026 ·
Earnings Reported Q3 2026 results: cash and short-term investments of $13.8 million, funding operations into 2H 2027. Net loss of $1.7 million, or $0.24 per share, included a $3.1 million noncash gain. Phase 1b PH data and CM5480 IND are expected mid-2027. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 16, 2026 ·
Leadership CFO Stephen Bardin resigned effective after the Form 10-Q for the quarter ended September 30, 2026 is filed, to pursue another professional opportunity. The resignation was not due to any disagreement with the company. Form 8-K · SEC filing
Sep 30, 2026 ·
Financing CalciMedica filed a prospectus supplement for an at-the-market offering of up to $25,000,000 of common stock through H.C. Wainwright & Co., with a 3.0% commission. The last reported sale price was $1.695 per share on September 28, 2026. Form 424B5 · SEC filing
Sep 30, 2026 ·
Financing CalciMedica filed a prospectus supplement under its effective Form S-3 for an at-the-market sale of up to $25,000,000 of common stock through H.C. Wainwright & Co. under an agreement dated August 11, 2023. A Cooley LLP legality opinion is attached as Exhibit 5.1. Form 8-K · SEC filing
Sep 16, 2026 ·
Listing CalciMedica regained compliance with Nasdaq's minimum bid price requirement after its closing bid stayed at $1.00 or greater for 10 consecutive business days, from August 31, 2026 to September 14, 2026. The company has no outstanding Nasdaq deficiency notices. Form 8-K · SEC filing
Sep 2, 2026 ·
Listing Nasdaq closed its market value of listed securities deficiency after stockholders' equity of $5,513,000 met the alternative requirement. The bid price deficiency remains open until September 14, 2026, following a one-for-five reverse split on August 28, 2026. Form 8-K · SEC filing
Aug 27, 2026 ·
Listing CalciMedica will effect a 1-for-5 reverse stock split and cut authorized common shares from 500,000,000 to 100,000,000, effective 5:00 p.m. ET on August 28, 2026. Trading resumes split-adjusted on Nasdaq on August 31, 2026 under CALC. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
May 2024 · Phase 2 · Results Expected · A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS Registry primary completion date, not a results date
Jun 2021 · Phase 2 · Results Expected · A Study of Auxora in Patients With Severe COVID-19 Pneumonia Registry primary completion date, not a results date
Mar 2019 · Phase 2 · Results Expected · A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis Registry primary completion date, not a results date
Feb 2019 · Phase 2 · Results Expected · CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CALC holds $13.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.2M/quarter from operations,
an estimated runway of 9.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:70 · High
Cash runway 10 months +30
ATM program on file since Nov 2025 +15
Shelf registration (S-3, Mar 2026) +10
Going-concern doubt in the latest 10-Q +15Our need for additional capital raises substantial doubt about our ability to continue as a going concern.10-Q, Nov 2026
Share count 6,895,149 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CALC picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CALC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.